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ABSTRACT
Given the process of tumorigenesis, biological signaling pathways have be-
come of interest in the field of oncology. Many of the regulatory mechanisms that
are altered in cancer are directly related to signal transduction and cellular com-
munication. Thus, identifying signaling pathways that have become deregulated
may provide useful information to better understanding altered regulatory mecha-
nisms within cancer. Many methods that have been created to measure the distinct
activity of signaling pathways have relied strictly upon transcription profiles. With
advancements in comparative genomic hybridization techniques, copy number data
has become extremely useful in providing valuable information pertaining to the ge-
nomic landscape of cancer. The purpose of this thesis is to develop a methodology
that incorporates both gene expression and copy number data to identify signaling
pathways that have become deregulated in cancer. The central idea is that copy
number data may significantly assist in identifying signaling pathway deregulation
by justifying the aberrant activity being measured in gene expression profiles. This
method was then applied to four different subtypes of breast cancer resulting in the
identification of signaling pathways associated with distinct functionalities for each
of the breast cancer subtypes.
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Chapter 1
INTRODUCTION
1.1 Signaling Pathways and Cancer
Signal transduction describe a series of molecular interactions where external cel-
lular signals induce an intracellular response. These responses can influence a cell
by creating protein products that induce transcriptional and metabolic behaviors.
The specific steps with respect to gene and proteins interactions that occur when
signal transduction is initiated can be described using biological signaling pathways.
Biological signaling pathways have become of significant interest in oncology due
to overwhelming evidence suggesting that tumorigenesis is largely linked to intra-
cellular and intercellular signal degradation and alteration. Hanahan and Weinberg
initially identified 6 specific steps that must occur to alter the inherent cellular reg-
ulatory mechanisms causing a normal cell to enter into a cancerous state [2]. Out
of the six original steps towards tumorigenesis, three were directly related to sig-
nal transduction. First, self sufficiency in growth signals is achieved, which is best
described as the process by which the autocrine signaling is used to induce self
growth without any assistance of signaling from other cells [3] . Second, insensi-
tivity to antigrowth signals is accomplished, which is defined as the breakdown of
paracrine signaling by which neighboring cells try to communicate to a rogue cell to
cease in growing without success. Finally, evasion of apoptosis represents a cul-
mination of breakdown of all signaling where apoptosis or programmed cell death
(pcd) of a rogue cell cannot be initiated internally by the rogue cell or externally by
neighboring cells. In addition, recent evidence has been presented suggesting that
cancer cells rely on interactions with normal cells in nearby surrounding areas form-
ing a complex micro-environment composed of a mixture of normal and cancerous
cells [4]. This has profound implications in that signal transduction networks are not
completely destroyed but rather altered to benefit a cancerous environment. Sig-
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naling pathway analysis, therefore, provides a starting point to identify and better
understand the blueprint of altered and re-wired signal transduction in cancer.
1.2 Current Data Available For Signaling Pathway Analysis
Microarray technology has revolutionized biology by expanding our insight into the
genetic inner-workings of a cell. Gene expression profiling has played an especially
critical role in understanding cellular processes by simultaneously measuring the
activity, also known as expression, of thousands of genes at once. Gene activity
can be measured based on the amount of messenger Ribonucleic Acid (mRNA)
that is produced or expressed. Strands of complementary Deoxribonucleic Acid
(cDNA) are first synthesized from mRNA using enzymes and marked with florescent
markers. The cDNA from different target genes are then introduced to a platform
called a microarray that contains thousands of known regions or sections of DNA
called probes. Using hybridization techniques, binding occurs between cDNA and
the probes. Using the florescent markers, image analysis is then done where the
intesity of the spots of each marker are converted into an expression value. Many
microarrays can be combined into an expression matrix, which is then transformed
into the famous heat maps that are commonly used in bioinformatics. This tech-
nology has proven to be extremely useful in the analysis of signaling pathways and
cancer as a whole.
A much newer method that has proven to be just as pertinent in cancer
research is that of array-based Comparative Genomic Hybridization aCGH, which
focuses on the genomic landscape of a cell. Each cell in the human body contains
the entire genome, with the exception of sex cells which are beyond the scope of
this thesis. In order to maintain a healthy state, a cell must keep intact as much
of it’s entire genome as possible and has regulatory mechanisms in place to do
so. If these regulatory mechanisms are compromised, significant aberrations and
mutations may occur in a cell’s genome. Tumorigenesis is directly linked to these
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mutations that occur on the genome of a cell. These mutations allow a cell to
bypass many biological safeguards that were intended to prevent disruption of nor-
mal cellular functionality causing it to enter a highly proliferative, uncontrolled state.
Cancer cells are unique in that they reproduce defying normal restraints on cells,
metastasizing and colonizing in other biological environments normally reserved for
other cell types [3]. Thus, it is quite conceivable to ascertain the health of a cell by
analyzing its genomic structure. The method employed by aCGH is based on the
same principles as gene expression profiling. However, there are some significant
differences worth noting. First, a test cell and a reference cell’s DNA are cleaved
using different enzymes into smaller portions depending on the size of the DNA se-
quence or window that is selected. The smaller the window selected the larger and
more specific the resulting data set is. Next, each cell’s DNA is labeled differently
to discern one from the other using florescent markers. They are then hybridized
to thousands of probes and the resultant intensity ratio is used to measure copy
number alterations in the test cell. The aCGH technique has proved beneficial in
providing the data needed to develop methods for better understanding the genomic
structure of different types of cancer such as breast cancer and glioma [5, 1]. Copy
number data has also been important in signaling pathway research, though, to a
much less extant as its gene expression counterpart.
1.3 Weighted Signaling Pathway Impact Analysis with GISTIC Genes
(WSPIAGG)
Inspired by two robust algorithms, Signaling Pathway Impact Analysis (SPIA) and
Genomic Identification of Significant Targets In Cancer (GISTIC) method, Weighted
Signaling Pathway Impact Analysis with GISTIC Genes (WSPIAGG) was devel-
oped for signaling pathway analysis. This method incorporates the use of gene
expression data with copy number data to better understand the impact that gene
mutations have on expression data impacting signaling pathways. In addition, in-
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teractions in each pathway are verified through the use of cellular context mining
(ccm), a powerful tool capable of recognizing gene regulatory relationships in gene
expression data. The overall purpose of combining these methods was to give more
credence to pathways that contained mutated genes where sufficient evidence ex-
ists that they may be influencing the activity of other genes within a given pathway.
1.4 Organization Of Thesis
The framework and origins of the WSPIAGG method is provided in the background.
WSPIAGG is formally defined in chapter 3. Since often times methodologies be-
come too complex and incapable of being implemented, chapter 3 also describes
its implementation. Chapter 4 describes the real-world application of WSPIAGG
by applying it to breast cancer data sets. The method is then compared against
the original SPIA methodology analyzing performance of identifying pathway activ-
ity as well as the average score given across different tumor samples. Chapter 5
provides an explanation for the differing results when comparing the two method-
ologies. Given that the expansion of WSPIAGG to use other data and tools is quite
feasible in the not too distant future, chapter 5 also describes future works.
4
Chapter 2
BACKGROUND
2.1 Pathway Analysis
Several methods for analyzing signaling pathways using transcription profiles have
been developed. Original methods focused on overrepresentation analysis (ORA)
of differentially expressed genes within a pathway [6]. However, as understand-
ing of signaling pathways have increased, the methodology to determine signaling
pathway deregulation has improved.
Some methods focused on determining the activity of signaling pathways in
gene expression profiles based on the gene activity of target genes. If a pathway
is deregulated, transcription factors influenced in a signaling pathway will affect the
expression of its target. This was suggested given that signaling pathways may be
deregulated and not display transcriptional activity of it’s member genes. Breslin
et al. demonstrated that analysis of downstream target genes within a sample was
a viable option for identifying signaling pathway deregulation [7]. Liu and Ringner
further proposed analyzing transcription factors that mediated signaling pathways
and using corresponding cis-regulatory motifs to identify potential genes that may
show activity if a given pathway were to be deregulated [8]. Both cases used knowl-
edge of transcription factors and target genes to determine deregulation of signaling
pathways. However, gene regulatory networks within a signaling pathway were not
taken into consideration in both methods when identifying deregulation.
Tarca et al. developed a method that incorporated the graph structure of a
pathway with the transcriptional activity of member genes to assess the full impact
of differentially expressed genes [9]. It was a significant improvement over other
pathway analysis methods that relied on ORA only or didn’t take into consideration
inherent gene regulatory networks when determining pathway deregulation. More-
over, it took advantage of pathway information from KEGG Pathway database to
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validate the different interactions types between genes. One of the core strengths
within this method was that it did not try to replace ORA analysis but rather com-
plement it through the introduction of a novel algorithm known as the pathway per-
turbation factor. This perturbation factor measured how a gene might propagate
its influence on genes that are downstream of it in a given pathway. Another core
strength was its robustness and ability to allow for implementation of strengthening
the known interaction between two genes in a pathway. The WSPIAGG method
was built upon this method because of these core strengths.
2.2 Context-Specific Gene Regulatory Network
Gene expression data has proven useful in giving an overall picture of a tumor sam-
ple’s gene activity, but it has been quite difficult to discern how this activity explains
cellular states and the corresponding genetic interactions. In an effort to better ex-
plain the interaction of genes being regulated in the different states or contexts of
a cell, Doughtery et al introduced a mathematical model for describing contextual
gene regulation [10]. This mathematical model assumes that within a specific con-
text there are M sets, G1, G2, ..., GM , of driver genes and m corresponding sets,
S1, S2,..,Sm, of driven genes and that for each driven set Sj there is a driver set
Gj that is governing the behavior of genes in Sj. The significance of this fact is
self evident when environmental factors that cause mutations of a gene may corre-
spondingly change other gene expressions. Transcriptional changes could impact
normal regulatory mechanisms and, thus, change the overall state of a cell.
A cell enters into a cancerous state when normal regulatory mechanisms
have changed and adjusted to environmental factors to provide proliferative signals
and usurp inherent biological safeguards intended to prevent abnormal cells. Can-
cerous cells may eventually create micro-environments that retain a complex, con-
sistent, and reliable regulatory machinery that is required for a cell to survive and
proliferate. In taking advantage of potentially consistent transcriptional behavior
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within a cellular state, Kim et al. developed an algorithm that uses gene expression
data to identify the relationship between sets of genes within a specific biological
state known as a context motif [11]. A context motif can be thought of as the state
of a cell defined by the transcriptional activity of a set of genes regulating another
set of genes within a subset of samples that share some phenotypic attributes. The
two key statistical parameters that are used to determine the activity and regulation
of genes within a specific context motif are interference and cross talk. The interfer-
ence of a gene in a context motif is defined as "the extent to which latent variables
(external controls sensitive but not specific context motif) interfere with regulatory
signals from a master gene, Gj" [11].
δjk = 1− Pr(gk = ON |C = cj) (2.1)
The crosstalk of a gene is defined as the probability that the gene, gk is
being regulated (by external control), when the cellular context is not cj .
ηjk = Pr(gk = ON |C 6= cj) (2.2)
Context motifs hold two important graph structure properties that are worth
noting. First, the driver-driven relationship between sets of genes within a context
motif form a directed graph. Second, a gene may be a driver gene in one context
motif while simultaneously being a driven gene in another displaying an overlapping
community structure that is often seen in nature [12, 13]. Noting the inherent graph
properties of context motifs identified in cellular context mining, Sen et al. devel-
oped a method of formally constructing context-specific gene regulatory networks
from context motifs [14]. Through the combination of various context motifs that had
overlapping genes and taking advantage of the directionality of interaction, an inter-
esting graph structure emerged representing a community of genes regulating one
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another. Thus, the overall graph structure was called a context-specific -gene regu-
latory network (GRN). The context-specific GRNs were then grouped based on the
sparsity of edges seen by the human eye. The different groups identified were clas-
sified as contexts since they represented overlapping gene activity between groups
of context motifs. A sample association score was then developed to determine, as
its name implies, which context a tumor sample was closely associated with.
SAS(s, C) = m
√√√√ m∏
i=1
fi(s) where fi(s) =

ki/N, s ∈ Ci
1, otherwise
(2.3)
where ki is the number of samples within a context Ci and N is the total number
of samples in the gene expression data. Sen et al. demonstrated that given a
mixture of tumor samples pertaining to different cancer types, the resultant contexts
formed from the different tumor samples analyzed were statistically enriched with
the different types of cancer [14].
Ramesh et al. further investigated the graph structure of context-specific
GRNs by comparing the contexts that resulted from applying two different cluster-
ing algorithms [15]. Traditionally, bottom-up or agglomerative approaches in hier-
archical clustering have been applied to transcription profiles to identify groups of
significantly important genes. However, this approach has two limitations that would
prohibit use on context-specific GRNs. First, the time and space complexity for m
data points can reach as high as O(m2 logm) and O(m2) , respectively [16]. Given
the size of nodes or data points and the density of edges, it would not be efficient or
even feasible in applying to context-specific GRNs. Second, given its bottom up na-
ture, hierarchical clustering used in transcription profiles lacks any global objective
[16] which is paramount in context-specific GRNs given the relationship between
different context motifs. Thus, two clustering algorithms were selected that imple-
mented a top-down or divisive approach while taking into consideration the global
view of the data. Markov Clustering Algorithm (MCL) [17] and spectral clustering
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[18] were applied to context-specific GRNs to verify if any significant biological in-
ferences could be gleaned in and efficient manner. Contexts obtained from spectral
clustering and MCL clustering were compared on a number of different attributes
such as connectivity density within and between clusters. These different con-
texts were also analyzed for enrichment of different cancer types that occurred with
statistical significance. The significance of this study implicates that transcription
profiles from different types of cancer may be grouped together from a top-down
approach and still yield significant results when implemented with context-specific
GRNs. MCL clustering provided a much more robust method given that one does
not need to identify the number of cluster beforehand. Moreover, MCL performed
comparably well if not better than spectral clustering with respect to coverage and
performance values [15]. Thus, the use of contexts clustered using MCL were the
cornerstone of inferred interaction data in WSPIAGG.
2.3 Genomic Identification of Significant Targets In Cancer (GISTIC)
With respect to genomic structure, the GISTIC method [1] proved to be efficient
and simple in its application and extremely useful in taking chromosomal data and
translating it into pertinent information of cancer . The method first identifies differ-
ent areas of chromosomal aberrations across a set tumor samples. The method
then assigns a G score to these previously identified areas based on the total mag-
nitude of aberrations, in essence, summing them up. These aberrations are then
permuted in each sample across the genome and the G score is recalculated to de-
termine the probability of finding the observed G score by random chance. Those
aberrations with high amplitude consistent across the samples are considered sig-
nificant in the respective type of cancer that the tumor samples are associated with.
Genes that are found within regions identified by the GISTIC method are termed
GISTIC genes and are used for further analysis in WSPIAGG.
9
Figure 2.1: GISTIC algorithm overview provided by [1]
This method has assisted in identifying chromosomal regions of significance
in both glioma and breast cancer [1, 5]. Moreover, in the particular case of breast
cancer it was used to assist in the identification of six subtypes of breast that shared
similar clinical characteristics [5].
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Chapter 3
WEIGHTED SIGNALING PATHWAY IMPACT ANALYSIS with GISTIC GENES
(WSPIAGG)
The WSPIAGG scoring method is a combination of three different methods that
have proven useful in cancer research. It improves the original Signaling Pathway
Impact Analysis (SPIA) [9] in two distinct ways. First, it incorporates data from
Cellular Context Mining (CCM) to strengthen gene interactions in a pathway where
evidence exists. The original SPIA method allowed for specifying the strength of the
interactions given that a fixed value be defined for the different types of interactions
in KEGG database [19]. The use of CCM is much more dynamic, strengthening
interactions based on gene-pair interactions inferred through real world evidence in
the form of gene expressions profiles. Second, genes identified through the use
of the GISTIC method are used in determining the significance of any perturbation
measured. The GISTIC method introduce the ability to identify specific genes that
may be of importance in signaling pathways where aberrant activity has been mea-
sured. It incorporates a necessary component of genomic structure in signaling
pathway analysis. The original SPIA method is also quite efficient in calculating the
perturbation scores as will be demonstrated using vectors and matrices. The WSPI-
AGG method will build upon this efficiency in modifying the original methodology as
well as in computing the newly introduced values.
3.1 Original Signaling Pathway Impact Analysis (SPIA)
Signaling Pathway impact analysis (SPIA) combines two independent forms of ev-
idence in the analysis of signaling pathways. The first is the traditional form of
overrepresentation analysis (ORA), obtaining the probability of finding a set of dif-
ferentially expressed genes within a pathway. ORA is well known for its simplicity
and reliability and is traditionally used in extracting useful information from gene
expression profiles. ORA is done by finding the number of pathway genes that
11
Member Set Non-member
Set
total
Differentially Expressed d m− d m
Normally Expressed n− d N + d− n−m N −m
total n N − n N
Table 3.1: Hypergeometric Distribution
are differentially expressed versus the number of pathway genes with no differen-
tial expression given the total pathway genes found in the gene expression profile.
The probability PNDE of finding a given number of differentially expressed genes is
calculated using the hypergeometric distribution.
P (M = m) =
(
m
d
)× (N−m
n−d
)(
N
n
) (3.1)
In an ideal scenario, expression data would exist for every gene in a path-
way. However, at this point no pathway repository contains this amount of informa-
tion. Therefore calculating the enrichment of differentially expressed genes, DEg,
within the confines of a set of pathway genes, Pg , must be done by taking the inter-
section, Pg ∩DEg, of the two to represent d while N should equal the intersection,
Tg ∩ Pg , of all genes with gene expression data, Tg, and pathway genes, Pg.
The second form of evidence used in SPIA is referred to as the perturbation
analysis. This analysis exploits the graph structure created by gene member inter-
actions to determine the full impact of a differentially expressed gene in a signaling
pathway. This is imperative to help mitigate some of the short-comings that simple
overrepresentation analysis has. A useful demonstration provided by Tarca et al [9]
compared two hypothetical pathways that have the same number of differentially
expressed genes but differ in which genes are differentially expressed.
As demonstrated by the comparison examples, the two pathways will have
the same enrichment p-value associated with them. However, given the graph
12
G2
G1
G3
G4
G5 G6
(a) Pathway 1
G2
G1
G3
G4
G5 G6
(b) Pathway 1′
Figure 3.1: Comparison of pathways could yield similar gene enrichment results
structure of Pathway 1′, it is much more likely of extracting useful information from
gene interactions than Pathway 1. This is because genes that are further upstream
of other genes and are differentially expressed have a much higher probability of
influencing downstream genes. Perturbation analysis takes advantage of the graph
structure by measuring the accumulated perturbation within a pathway. The amount
of perturbation is measured at a single gene in a pathway using a perturbation fac-
tor PF (g).
PF (g) = ∆E(gi) +
n∑
j=1
βij × PF (gj)
Nds(gj)
(3.2)
where ∆E(gi) represents the signed normalized measured expression change of
gene gi in a sample.
The expression of gene gi is added to the sum of perturbation factors of di-
rectly upstream genes gj , normalized by the number of downstream neighbors that
each gj has, Nds(gj). The strength of the interaction between genes gi and gj is
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Gene ∆E PF Acc
G1 0 0 0
G2 0 0 0
G3 1.5 1.5 0
G4 2 2 0
G5 0 0 0
G6 0 0 0
Total Acc 0
Table 3.2: Pathway 1
Gene ∆E PF Acc
G1 1.5 1.5 0
G2 2 2.5 0.5
G3 0 1.25 1.25
G4 0 1.25 1.25
G5 0 .5 .5
G6 0 .5 .5
Total Acc 4
Table 3.3: Pathway 1′
quantified through the absolute value of βij , while the directionality is represented
by assigning βij a value of 1 corresponding to activation and -1 corresponding to
inhibition. Thus, a resultant matrix, β, is used to represent the strength and direc-
tionality of interaction from gene gj to gi .
β =

β11 β12 · · · β1j
β21 β22 · · · β2j
...
...
. . .
...
βi1 βi2 · · · βij

The perturbation factor rewards differentially expressed genes that have the
potential to influence other genes in a pathway making use of a pathway’s graph
structure.
Tarca et al. demonstrated that if similar expression values were assigned
to each of the differentially expressed genes within Pathway 1 and Pathway 1′ the
total perturbation accumulation would be significantly higher in Pathway 1′ [9] .
The importance of the position of each differentially expressed genes in a
pathway K is, therefore, captured and given a quantifiable score. In order to en-
sure that disconnected genes are not considered in perturbation analysis and that
the gene expression of gene gi is not double counted in ORA and perturbation
analysis, the gene expression of gene gi, ∆E(gi), is subtracted from the perturba-
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tion factor measured at gi. This value is considered an accumulated perturbation
measurement, Acc(gi), at level gi .
Acc(gi) = PF (gi)−∆E(gi) (3.3)
An Acc vector containing the accumulated perturbation for each gene in
a pathway can efficiently be calculated by setting Bij to equal βij divided by the
number genes that are downstream, Nds(gj),of gene gj .
B =

β11
Nds(g1)
β12
Nds(g2)
· · · β1j
Nds(gj)
β21
Nds(g1)
β22
Nds(g2)
· · · β2j
Nds(gj)
· · · · · · . . . · · ·
βn1
Nds(g1)
βn2
Nds(g2)
· · · βnj
Nds(gj)

Applying the following equation will yield the resultant accumulation vector.
Acc = B · (I −B)−1 ·∆E (3.4)
where ∆E is the vector of all gene expression values in a pathway.
∆E =

∆E1
∆E2
...
∆En

I is simply an n×n identity matrix where n represents the number of genes
in a pathway.
The total accumulated perturbation in a pathway could then be computed by
summing the resultant Acc vector.
tA =
n∑
i=1
Acc (3.5)
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Tarca et al. demonstrated that higher total accumulated perturbations were
less probable in a pathway then lower accumulated perturbations. The probabil-
ity of finding this score by random chance is calculated using a simple bootstrap
technique with replacement. The bootstrap technique can be defined as for each
pathway K, a set of Nde(Pi) differentially expressed gene IDs intersecting path-
way K and the gene set of the complete gene expression profile are selected and
a random perturbation accumulation score TA(K) is re-calculated. This process is
conducted Nite times where the larger the number the more accurate the probability
will be. The random median perturbation accumulation score TA is then calculated
and subtracted from the random accumulation scores TA(K) to center the distri-
bution around 0 giving TA,c(K). In addition, the median TA is subtracted from the
observed pathway score to correct for the shift in the null distribution median giving
tA,c. The probability PPERT is obtained using the following equations.
PPERT =

2×
∑
k I(TA,c(K)≥tA,c) if tA,c ≥ 0
Nite
2×
∑
k I(TA,c(K)≤tA,c) otherwise
Nite
(3.6)
If tA,c > 0 then the pathway is considered activated and if tA,c < 0 then the
pathway is considered inhibited.
The p-value associated with each of the evidences was than combined using
PG = ci − ci · ln(ci)
where ci = PPERT · PNDE. This method proved superior to the use of only ORA on
a pathway as was demonstrated by Tarca et al. [9].
3.2 Improving SPIA
Building upon the concepts introduced by SPIA, two main areas will be strength-
ened. The first is the use of transcription profile data in conjunction with cellular
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Figure 3.2: Edges are strengthened using Context-Specific GRN
context mining (CCM) from the tumors being analyzed to strengthen the putative
interactions in pathways. The second is the introduction of copy number data in
assisting with the identification of genes that may be causing a pathway’s aberrant
activity. Each of these contributions will provide a new level of accuracy in deter-
mining pathway deregulation.
Context-Specific Gene Regulatory Networks Improves Quality Of Putative Data
The robustness of the SPIA method is due to to its ability of allowing the strength-
ening of the putative gene interaction through modification of βij . Original results
generated by Tarca et al. on colorectal cancer datasets used |β = 1| in order to
minimize the number of model parameters in the research conducted [9] . How-
ever, strengthening putative interactions in a given pathway with reliable data ob-
tained from the actual sample expression profiles would be ideal given the nature
of cancer. As such, context mining was augmented to support putative interactions
in a pathway. Context mining has proven to infer useful insight into driver-driven
relationships between genes across different samples of expression data in can-
cer [11, 14, 15]. Using context mining, different states known as context motifs,
CM , consisting of a gene or set of genes that have a high statistical probability of
influencing another set of genes can be identified. A context-specific gene regula-
tory network (GRN) can then be constructed based on the gene overlap between
different context-motifs. However, the resultant GRN may be huge making further
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Figure 3.3: (a) Markov Clustering Results [TN study]. (b) Asymmetric Spectral
Clustering Results [TN study]. Clustering previous data resulted in identification of
contexts enriched with different cancer types.
analysis quite cumbersome if not impossible.
My previous published works of clustering context-specific GRNs into more
manageable networks or contexts was shown to be a viable option capable of iden-
tifying multiple clusters enriched with different types of cancer [15]. In particular,
MCL proved to be useful and efficient in its application with respect to tumor analy-
sis and therefore is used to split the resultant context-specific GRN’s.
This allows for the further strengthening of putative gene interactions when
analyzing gene expression profiles from samples across different types or even
subtypes of cancer. The strengthening of the interaction between two genes is sim-
ply done by taking the inverse of the summed number of nodes traversed (hops),
GRNHij , from gene gi to gj in the context-specific GRN and adding it to the ab-
solute value of the putative interaction then reapplying the original sign value as as
shown in equation 3.7.
β
′
ij = pij × (1 +
1
GRNHij
) (3.7)
where pij is the putative interaction value in a pathway between two genes.
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GRNHij =
h∑
1
1 +  (3.8)
A user-defined error, , can be added to each hop that is outside the cluster
of those enriched by the subtype of the sample expression profiles being analyzed.
The hops value, GRNHij , transforms βij into a stronger β
′
ij dependent upon the
composition of a context-specific GRN. Thus, an optimal scenario can be consid-
ered as gene gj having a summed hops value to gene gi of GRNHij = 1 indicating
that strong evidence exists in the expression profile that gene gj is influencing gi.
This scenario would double the strength of the interaction between gene gj and
gene gi and therefore increase the accumulated perturbation in the original SPIA
method transforming the original perturbation factor into.
PF
′
(g) = ∆E(gi) +
n∑
j=1
β
′
ij ×
PF (gj)
Nds(gj)
(3.9)
In order to compute Acc′, a matrix GRNH is derived with values represent-
ing 1 divided by the number of nodes traversed (hop value), GRNHij , from genes
gj to gi within the clustered context-specific GRN.
GRNH =

1
GRNH11
1
GRNH12
· · · 1
GRNH1j
1
GRNH21
1
GRNH22
· · · 1
GRNH2j
...
...
. . .
...
1
GRNHi1
1
GRNHi2
· · · 1
GRNHij

Applying the GRNH matrix to the B matrix represents the strengthening of
the interactions forming B′.
B′ = B + (GRNH × β)
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In order to preserve the same interaction sign, GRNH is first multiplied by
the β before adding it to B. The weighted accumulated perturbation vector, Acc′,
was then derived using the following equation as specified in [9].
Acc′ = B′ · (B′ − I)−1 ·∆E
The sum of the Acc′ vector represents the total modified accumulated per-
turbation of a pathway t′A =
∑
Acc′. Random scoring is done Nite > 2000 to keep
the same random scoring parameters as those described in the original SPIA [9]
for generating P ′PERT .
Copy Number Data Provides Useful Insight Into Deregulation
The SPIA method is quite useful in measuring the potential activity of a pathway
but does not make an attempt to explain the origins of such activity. To this extent,
knowing the molecular structure of genes within a pathway may better explain why
such aberrant activity is occurring. Similar to the original SPIA method, two forms
of evidence are used in determining the significance of genomic aberrations in a
signaling pathway.
The first evidence is the enrichment analysis of a specific type of mutated
gene known as a GISTIC gene. These GISTIC genes are derived from areas of
chromosomal aberrations identified through the use of the Genomic Identification of
Significant Targets In Caner (GISTIC) method. As previously discussed, the GISTIC
method has been extremely useful in its application to cancer datasets. Therefore,
analyzing pathways for GISTIC gene members could provide crucial evidence for
deregulation analysis. Fisher’s exact test is used to determine the probability of
finding a number of GISTIC genes in a given pathway randomly, identifying these
pathways as potentially significant in the cancer subtype being analyzed. Only the
intersecting set, GG ∩Dbg, of GISTIC genes, GG, and those genes located in the
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Fisher’s Exact Test For Pathways
In Pathway Not In Pathway
GISTIC Genes a b
non-GISTIC Gene c d
Table 3.4: Fisher’s exact test for a set of GISTIC genes found in a given pathway
database the pathway originated from, Dbg, were considered as the total number
of GISTIC genes, a+ b, when calculating the p-value.
The less likely the number of GISTIC genes in a pathway are, the more like-
lihood that they may play a role in the activity of a pathway if it is deregulated. This
supported by the fact that chromosomal aberrations identified using the GISTIC
method have proven to be quite useful in classifying subtypes of cancer with similar
clinical characteristics [5, 1]. Moreover, many of the GISTIC genes identified within
these areas of aberration have shown to be quite interesting with respect to their
functional annotations. Therefore, they are used as markers in identifying signaling
pathways that may be potentially deregulated. Any pathway that’s member genes,
Pg, intersect the set of GISTIC genes, GG, are considered to be in a potentially
deregulated state, PDS, and are tagged for further investigation of errant activity.
Pg ∩GG→ PDS
The second form of evidence is scoring GISTIC genes on the basis of contri-
bution to perturbation, high-throughput data agreement, and graph structure place-
ment. Since Fisher’s exact test is simply another tool for ORA, it faces the same lim-
itations as previously discussed for enrichment analysis of differentially expressed
genes in that the graph structure and placement of these genes is neglected. Thus,
the true impact that GISTIC genes have in potentially altering a pathway may be
severely restricted to a simple explanation of being found in the pathway. In order
to mitigate these issues, the role that GISTIC genes have in altering pathway ac-
tivity is captured using a gene influence GINF scoring component. This scoring
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component measures the influence of each gene on the total accumulated pertur-
bation, Acc, of a pathway as captured by the original SPIA method. The GINF
score is formally described as
GINF (gj) =
n∑
i=1
gInfji × 1
pathwayHopsgji
×HTA(gj) (3.10)
where gInfji represents the amount of perturbation introduced to the accumulated
perturbation at gi from gj .
gInfji =
|maxPF (gj)|
|Acc′(gi)| (3.11)
where maxPF (gj) represents the maximum perturbation factor gene gj may in-
troduce to the perturbation accumulation measured at any gene gi in a pathway.
Let us assume that in a given pathway, gene gj is differentially expressed and has
only out going edges then finding the maximum perturbation factor, maxPF (gJ),
passed to downstream neighbor genes is simply the measured expression of gene
gj divided by the total number of downstream genes Nds(gj).
maxPF (gj) =
∆E(gj)
Nds(gj)
(3.12)
Since biological networks and, more specifically, signal transduction net-
works display scale-free network properties that are sparsely connected [20, 21,
22], the use of the maximum perturbation factor to calculate gInf at any given gene
gi in a pathway ensures simplicity while maintaining a confident standard of accu-
racy. Let us return to figure 1 to gauge how GINF measures two different genes
dependent upon the location with respect to the graph topological structure. The
influence that gene G1 and gene G2 have on pathway P1′ can be demonstrated in
the following example.
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(a) G1 influence on Pathway 1′
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(b) G2 influence on Pathway 1′
Figure 3.4: Comparison of influence on pathway P1′ between genes
Gene ∆E maxPF GINF
G1 1.5 0.5 3.8
G2 2 1 1.6
G3 0 0 0
G4 0 0 0
G5 0 0 0
G6 0 0 0
Table 3.5: Gene Influence Score for each differentially expressed gene in Pathway
1′ taking into consideration only maxPF
This is a simple yet reasonable approach in calculating the potential influ-
ence of gene neighbors on a gene gi, however, as can be seen in tables 3.2 and
3.3, the maximum perturbation factor of gene gj continues to trickle down passed
its direct neighbor genes. In order to better reflect the potential direct and indirect in-
fluence on other genes in a given pathway, gInf is divided by the number of nodes
traversed within a pathway from gi to gj (hops) as represented by pathwayHopsgji .
This has two necessary effects on gene influence measurement. The fist is that it
rewards genes that are directly connected which is essential in a scale-free topolog-
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ical network. Second, it represents a reasonably assumed degradation of influence
as gj is further separated from gi.
The last term in theGINF equation ensures agreement between high through-
put data being used, which in this case is gene expression measurements and copy
number data. This term is referred to as High Throughput Agreement (HTA) and
is defined by equation 3.13.
HTA(gj) = 2×K
Sgexj×Scnaj
2 (3.13)
whereK is a specified value representative of the confidence of the high-throughput
data, Sgexj is a variable related to gene expression data of gene gj , and Scna is a
variable related to the copy number data of gene gj . In it’s simplest form K = 1
and ternary values are used for Sgex and Scna. Ternary values would represent the
state of the gene expression, Sgex, at a specified threshold where 1 is up-regulated,
−1 is down-regulated, and 0 is normal. Similarly, ternary value would represent
the state of the copy number, Scna, at a specified threshold where 1 is gain, -1 is
deletion, and 0 is normal. HTA rewards genes that have copy number and gene
expression aberration evidence in agreement and slightly penalizes those that have
aberration evidence that contradicts each other. Those where a ternary state of 0
is present in the high throughput data are neither penalized nor rewarded. The
concept is easily grasped by plotting the ternary states of the high throughput data
on a two-dimensional coordinate system as displayed in figure 3.5.
Thus, those points with a positive slope are rewarded, those with a negative
slope are slightly penalized, and those with a slope of zero are left alone. Formally,
the HTA value is given by taking the distance from a point and raising it to the
power of the resultant slope.
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Figure 3.5: States pertaining to high throughput data for a given gene plotted in
Cartesian coordinate system
HTA(gj) = (
√
(Scnaj − 0)2 + (Sgexj − 0)2)
Scnaj−0
Sgexj−0
Using a Karnaugh map to display the reward and penalty values for HTA, identify-
ing a simplistic and elegant equation becomes much more intuitive and is used to
formulate equation 3.13.
1.41 1.00 0.71
1.00 1.00 1.00
0.71 1.00 1.41
1
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Similar to the SPIA method, efficiently calculating the GINF (gi) score for
each gene gi in a pathway requires the use of matrix data structures.
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First, the vector maxPF is computed by simply doing a pairwise division of
the ∆E and Nds vectors.
maxPF = ∆E./Nds
where Nds is a vector representing the number of downstream genes for each gene
in a pathway.
Nds =

Nds(g1)
Nds(g2)
...
Nds(gn)

The HTA vector is then computed by letting ∆Etern and ∆Ctern represent
vectors of Sgexj and Scnaj for ever gene gj in a pathway using ternary values. An-
other vector, 2v, that’s size is equal to the number of genes in a pathway containing
a constant of 2 is also required.
2v =

2
2
...
2

HTA = ∆Etern. ∗∆Ctern
= HTA./2v
= 2v.HTA
Element wise multiplication of the vectors maxPF with HTA is then per-
formed.
gImp = maxPF. ∗HTA
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This vector is expanded where the vector was repeated as a row the number of
times needed to satisfy a square matrix.
gImp =

gImpg1 gImpg2 · · · gImpgn
gImpg1 gImpg2 · · · gImpgn
...
...
. . .
...
gImpg1 gImpg2 · · · gImpgn

Similarly, the modified Acc′ vector is expanded where the vector was re-
peated as a column the number of times needed to satisfy a square matrix.
AccM =

AccMg1 AccMg1 · · · AccMg1
AccMg2 AccMg2 · · · AccMg2
...
...
. . .
...
AccMgn AccMgn · · · AccMgn

Element wise division on gImp using AccM is then performed to give matrix
CGINF .
CGINF = gImp./AccM
The matrix CGINF represents what the gene influence for each gene would
be if the pathway was represented by a completely connected graph. It is, therefore,
necessary to determine the true topological structure of a pathway. The matrix PH
consisting of the nodes traversed (hops), phij , between genes gi and gj provides
the necessary topographical information. This information is obtained directly from
pathway databases . In order to find the shortest distance (hop count) between
each gene, Djikstra’s algorithm was used where the default distance was set to∞
indicating that no path exists from one gene to the next.
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PH =

ph11 ph12 · · · ph1j
ph21 ph22 · · · ph2j
...
...
. . .
...
phn1 phn2 · · · phnj

Element-wise division is then computed between CGINF and PH.
GINFM = CGINF ./PH (3.14)
The result is a matrix, GINFM , where the columns represent the influence
that gene gj has on gene gi. The sum of each column was computed to obtain the
vector GINF . This vector represents the score related to the amount of influence
that each gene has on the overall accumulation of a pathway.
Once the total GINF score has been found for each gene in a pathway,
GISTIC gene scores are compared against normal member gene scores. Using
Welch’s T-test, a p-value PGINF is obtained that describes the probability of finding
the average GISTIC gene influence on a pathway by chance given the average in-
fluence of the other member genes. This, ultimately, gives a clearer understanding
of the role that GISTIC genes play in pathway activity.
Combining P-values to determine significance of evidence
The p-values generated for each of the evidences used to determine whether a sig-
naling pathway was significantly altered were then combined using the Logit combi-
national method. Two p-values were specifically used for gene expression analysis
while the other two incorporated some form of copy number analysis as shown in
table 3.6.
In determining the best method to combine the p-values from the different
scoring components, one must fist specify an appropriate null hypothesis then de-
termine the importance of each p-value in accepting or rejecting the null hypothesis.
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Copy Number Evidence Gene Expression Evidence
Enrichment Analysis PNGG PNG
Perturbation Analysis PGINF PPERT
Table 3.6: A summary of p-value score generated for each type evidence analyzed
In addition, one must also determine and justify whether each p-value is indepen-
dent or dependent up on each other. Let us begin with a formal hypothesis as stated
here.
H0 =There are no subset of copy number altered genes that are causing
significant aberrant activity in a pathway.
In order to prove the alternative of this hypothesis, one must not only prove a
pathway is displaying aberrant activity but also that it is due to copy number altered
genes. Therefore each p-value obtained from the scoring method WSPIAGG is
important and should play some role in proving the alternative. In addition, the
independence of the first two scoring components was justified by Tarca et al. due
to the use of the boot strap procedure in computing PPERT and verified through
simulation of randomized pathways [9]. This leaves justifying the independence of
the final scoring components. Theoretically, it is justified given that copy number
data is generated completely separate from gene expression data. Moreover, the
method for identifying GISTIC genes do not rely upon any gene expression data.
The final scoring component PGINF independence is rooted in the basis that, similar
to PPERT , the true independence resides in network topology not gene expression
as demonstrated in the previous examples. Therefore, a method for combining
independent p-values assigning each a significant level of importance is required
Loughlin et al. compared several meta-analysis methods on different types
of data to ascertain which methods scored the best in rejecting a global null hy-
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pothesis when combing p-values [23]. Methods were compared changing different
parameters of the theoretical data such as number of null hypothesis to combine,
evidence distribution, and the strength of evidence in the null hypothesis. For com-
bining three or more p-values, Logit and normal scoring proved to be the most
powerful with respect to evidence distribution across all p-values [23]. Upon careful
consideration, the Logit method was chosen based on its performance in testing
and the ease of implementation.
L =
n∑
i=1
log(
p
1− p) (3.15)
where n is equal to the number of null hypotheses being tested. The distribution of
the Logit function has been shown to be a very close approximation to the normal
distribution function with a scaling factor of d ≈ 1.7 [24].
|Φ(x)−Ψ(dx)| < 0.1 (3.16)
where Ψ represents a normal distribution and Φ represents the Logit distribution.
To ensure the most simplicity and strength, the Logit method is what was
used to calculate the overall p-value of the null hypothesis.
3.3 Implementation
The theoretical formulation of such a multi-level, intense scoring mechanism must
be feasible for efficient implementation and application to real world data. Much of
the software used for implementation was proprietary and developed as required.
The two main languages that were used in software development were Java and R
project. The JRI library allowed for ease of implementation and collaboration be-
tween Java and R in implementing the original SPIA method as well as developing
novel aspects of the WSPIAGG method. Java was selected for its platform indepen-
dence and simplicity of use. R project was selected as the main statistical analysis
tool for its reliability, power in computation, and robustness in interacting with java.
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Netbeans 6.8 was used to develop different graphical user interface for ease of use.
JAMA matrix package was heavily relied upon to construct adjacency matrices and
assist in the implementation of SPIA in Java. In addition, previously developed
software known as EPiCC and ExPattern were used to infer context-specific GRNs
from quantized gene expression data.
High Throughput Data
Gene expression and copy number profiles were stored in R objects for ease of
access and use where the rows were representative of the corresponding copy
number and gene expression values of a given gene, and the columns represented
samples that the measurements were taken from. Both gene expression and copy
number data were also quantized for use in computing the high throughput agree-
ment value, HTA, and inferring context-specific GRNs.
Identifying Potentially Deregulated Pathways For WSPIAGG Analysis
A precompiled set of previously identified GISTIC genes was required for query-
ing publicly available pathway databases. Only signaling pathways from those
databases that offered web services for querying such as Pathway Commons and
KEGG were used.
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Chapter 4
DATA ANALYSIS AND RESULTS
4.1 Application To Breast Cancer Dataset
In order gauge the effectiveness of the WSPIAGG methodology, breast cancer data
containing copy number and gene expression profiles were used. WSPIAGG was
compared to SPIA to see how it performed across the different samples.
Tumor Samples Information
Breast cancer tumor samples were obtained from the Southern Sweden Breast
Cancer Group tissue bank, Skane University Hospital, Lund, the Helsinki University
Central Hospital, and Landspitali University Hospital [25, 5]. The median overall
survival follow up time was 8.1 years ranging from 0.24 to 32 years [25, 5]. There
were 346 primary tumors and the rest were attributed to local recurrences or lymph
node metastases [25, 5].
Gene Expresion Data
The global gene expression profiles of the 359 breast tumor samples consisted of
over 10,000 individual probes measuring mRNA using oligonucleotide microarrays
(Gene Expression Ominbus, GEO, platform GPL 5345) produced at the SCIBLU
Genomic Centre at Lund University [5]. Hybridization, labeling, and image analysis
were also all initially conducted at SCIBLU as described in [25]. The expression
data was normalized across an additional 218 breast tumor samples and the tu-
mor samples were classified accordingly into six intrinsic molecular subtypes first
defined by Hu et al [26]. NCBI entrez id mapping of gene symbols using DAVID
[27, 28] and HGNC [29] resulted in identifying ≈ 8200 unique probes as genes in
the gene expression profile. The median expression value was taken of those genes
that had more than one probe associated with it. The median was decided in order
to avoid potential outlying noise. A threshold of ±1 for normalized gene expression
data was used to determine differential expression for WSPIAGG analysis.
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Cellular Context Mining On Gene Expression Data
ExPattern software was ran with parameters of crosstalk = 0.3 and interference =
0.1 in inferring context-specific GRN. This resulted in the identification of 1,977
individual context motifs which were subsequently combined based on gene set
membership to form a heavily interconnected context-specific GRN using EPiCC
software. Clustering was performed on the context-specific GRN using MCL clus-
tering algorithm with an inflation parameter of 2.0. This value was selected given it’s
previous performance on cancer data [15]. A total of 94 different clusters of context
motifs known as contexts were identified. Samples were then assigned a context
or multiple contexts using the sample association score, SAS, with a threshold of
< 0.5. Each context was then analyzed for subtype enrichment using the hyperge-
ometric distribution to find the p-value, ps, which represents the likelihood of finding
a certain number of samples from a subtype of breast cancer by random chance
in a particular context. Contexts that had p-values ps < 0.001 were considered en-
riched with the subtypes of breast cancer represented by the tumor samples. This
ps value was used to define the introduced error associated with inter-context hops,
, in equation 3.8.
Copy Number Data
Copy numbers for approximately 32,000 clones were obtained using bacterial arti-
ficial chromosomes (BAC) microarrays (GEO platform GPL4723) produced by the
SCIBLU Genomics Centre, Lund University, Sweden, for each of the 359 breast
cancer tumors. Using R project to map clones to gene regions and DAVID and
HGNC for gene symbol to entrez id mapping yielded ≈ 7600 unique genes from
the probes. As with gene expression data, hybridization, labeling, image analysis,
normalization and break point analysis were conducted on the copy number data
at SCIBLU Genomic center as well [25, 5]. Gains and losses were identified by
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sample adaptive thresholds as described in [25]. Copy number thresholds were set
to ±0.2 in determining copy number deletion and gain for WSPIAGG analysis.
GISTIC Implementation On Copy Number Data
After determining regions of amplification and deletion, the GISTIC algorithm was
applied to the tumor samples to identify statistically significant amplification and
deletion peaks across the 359 tumor samples. Hierarchical clustering was con-
ducted using Pearson’s correlation on significant GISTIC peaks with complete link-
age on average scaled log2 ratio for each peak [5]. Six subtypes labeled Basal-
like, Luminal complex, Luminal simple, 17q12, amplifier, and mix, were identified
and had significant overlap with the six subtypes identified using Hu et al’s method
across the 359 tumor samples [5, 26]. Thus, Jonsson et al were able to demon-
strate that the genomic landscape as defined by the GISTIC method was capa-
ble of grouping tumor samples together that shared similar clinical characteristics.
Moreover, well known oncogenes such as MYC, HER2, and MDM2 were located
in aberrant regions of importance as well as demonstrating significantly correlated
gene expression levels [5].
Basal-like, Luminal complex, 17q12 and Luminal simple were selected for
pathway analysis given the clinical characteristics that each shared as well as dif-
fered from. From each of the four subtypes a set of genes was identified within
the respective GISTIC regions. There were 714 genes found in Basal-like GISTIC
regions, 770 genes found in luminal complex GISTIC region, 460 genes found in
17q12 GISTIC regions, and 393 genes found in luminal simple GISTIC regions.
Pathway Repositories
Four publicly available databases were used to obtain pathway information for initial
statistical analysis.
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Pathway Commons
Pathway Commons database is is a consolidation of other well known pathway
databases and is a collaboration between the University of Toronto and the Com-
putational Biology Center at Memorial Sloan-Kettering Cancer Center [30]. Since
Pathway Commons consists of pathway information from different databases, the
quality of the database is dependent on the quality of the consolidated databases.
Some of the more notable databases consolidated within pathway commons are
NCI nature, Reactome, and BioGRID. Pathways in Pathway Commons are stored
in BIOPax level 2 (BIOlogical PAthway eXchange) format. This database consists
of ≈ 5000 verified human genes and ≈ 1200 pathways. As of June 2011, path-
ways were stored in level 2 format incapable of identifying gene regulatory net-
works within signaling pathways. In the near future, the repository should transition
to BioPAX level 3 to resolve these issues.
Wikipathways
Wikipathways is an open and collaborative repository to create and edit pathways,
as the name implies, similar to Wikipedia [31]. It is maintained by BiGCaT Bioinfor-
matics (Maastricht University) and the Conklin Lab at the Gladstone Institutes (Uni-
versity of California, San Francisco). The creation and editing of these pathways
is made simple through the use of a graphical editing tool that caters to users with
different biological and computer backgrounds. Wikipathways uses GPML (Gen-
nMapp Pathway Markup Language) as it’s main pathway format. This database
consists of ≈ 4300 verified human genes with 369 pathways but given the ease
of pathway submission these numbers continue to grow. This, however, is also a
hinderance given the lack of standards in pathway development.
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KEGG
KEGG (Kyoto Encyclopedia of Genes and Genomes) Pathway database is one
of sixteen main databases under the well known and longstanding bioinformatics
resource named KEGG [19]. The entire KEGG resource is under the auspices of
the Kanehisa Laboratories at Kyoto University and the Human Genome Center of
the University of Tokyo. The pathways in the KEGG Pathway database are manually
created and stored in KGML (KEGG Graphic Markup Language) format. KEGG
Pathways contains ≈ 5000 verified genes with 389 pathways. The ease of access
to gene and pathway information makes it ideal for pathway analysis.
Biomodels
Biomodels database is a database that contains curated models that have been
peer-reviewed and published [32]. Although this database contains models, the dif-
ference between its models and pathways are one of information quantity. Mathe-
matical modeling is used in describing the interactions that occur in a model through
SBML (Systems Biology Markup Language) format. Moreover, controlled annota-
tions and related information are also available to the user. Thus, pathways would
be considered a single of component of many in a model. Although this database
provides much more information on models, and by definition pathways, it contains
a relatively small number of pathways compared to the others with only ≈ 600 ver-
ified genes and 326 curated pathways. The gene interaction information is also
quite cumbersome to extract and not suitable for the type of pathway analysis that
is within the scope of this thesis.
Of the four pathway repositories queried, only Wikipathways and KEGG re-
sults were selected for further pathways analysis since Pathway Commons and
Biomodels were not conducive to WSPIAGG pathway analysis. In the case of path-
ways commons, it provided a significant amount of pathways but was limited in
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scope to only protein-protein interaction (PPI) data. This is due to Pathway Com-
mons using BioPAX level 2 and the inherent restrictions within this specific level
[33]. Biomodels provided a significant amount of information pertaining to bio-
chemical interactions between molecules but proved to be extremely complex in
extracting simple gene interaction information.
The rules defining an edge and its ternary value were based on those in
the original SPIA method for KEGG pathways. The task of defining rules proved
to be much more complex for Wikipathways given that the original file a pathway is
created in is based on graphical syntax. Therefore, an approximation of what con-
stituted an interaction was based on line objects and the shape of their endpoints
where arrows indicated activation and t-bars indicated inhibition. Group to group
interactions were excluded given that there was a higher probability that group to
group indicated a transitioning from one biochemical state to the next as opposed
to influence or regulation.
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Interaction Type Edge Value
activation 1
compound 0
binding/association 0
expression 1
inhibition -1
activation_phosphorylation 1
phosphorylation 0
indirect 0
inhibition_phosphorylation -1
dephosphorylation_inhibition -1
dissociation 0
dephosphorylation 0
activation_dephosphorylation 1
state 0
activation_indirect 1
inhibition_ubiquination -1
ubiquination 0
expression_indirect 1
indirect_inhibition -1
repression -1
binding/association_phosphorylation 0
dissociation_phosphorylation 0
indirect_phosphorylation 0
Table 4.1: KEGG interactions definition for edge values
Interaction Type Edge Value
gene-gene→ 1
gene-gene a -1
group-gene→ 1
group-gene a -1
gene-group→ 1
gene-group a -1
group-group 0
Table 4.2: Wikipathways interactions definition for edge values
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Pathways that had an overall calculated p-value ≤ 0.05 were considered
significant and were selected for further analysis. Since there is much that is not
known of signaling pathway analysis and this type of analysis is still in its infancy,
it is best to cast a wider net while maintaining a certain confidence level to allow
biologists to make the final determination of significance.
4.2 Results
WSPIAGG was compared against SPIA in two different measurements. First, the
average p-value of all pathways was taken across the different samples of each of
the cancer subtypes analyzed. Those pathways that had a score for every sample
in a subtype were used to compare the two scoring methods. Secondly, the pathway
activity detected in the different subtypes were displayed as heatmaps using a p-
value threshold of ≤ 0.05 to determine activity status significance. Throughout the
different subtypes, a common pattern emerges in which more pathways are found
using the original SPIA method but more consistency is found using the WSPIAGG
method across the tumor samples for pathway deregulation.
Basal Like Analysis
Comparison Results
Previous research has linked Basal-like subtype to aggressive forms of cancer with
a worse prognosis then other subtypes such as luminal simple [5, 26]. Both SPIA
and WSPIAGG were able to identify pathways implicated in cancer such as the cell
cycle pathway and the focal adhesion pathway. However, WSPIAGG was found
to score these pathways much lower than SPIA implicating that the GISTIC genes
found in these pathways are complicit in the deregulation.
WSPIAGG was also able to identify more pathways consistently deregulated
across the tumor samples then SPIA. This indicates that much more differentiation
both genomic and expression wise was picked by WSPIAGG. One explanation is
that Basal-like subtype was highly associated with BRCA1 mutated tumors [5]. This
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WSPIAGG SPIA
pathwayName Ave P-value PahtwayName Ave P-value
Non-small cell
lung cancer
:path:hsa05223
0.0017 Complement
and Coagu-
lation Cas-
cades:WP558
0.1006
Prostate cancer
:path:hsa05215
0.0192 Complement
and coagula-
tion cascades
:path:hsa04610
0.1252
Focal Adhe-
sion:WP306
0.0624 ECM-receptor
interaction
:path:hsa04512
0.1429
Complement
and coagula-
tion cascades
:path:hsa04610
0.0668 Focal adhesion
:path:hsa04510
0.1461
Cell cycle
:path:hsa04110
0.1051 Focal Adhe-
sion:WP306
0.1629
DNA damage
response (only
ATM depen-
dent):WP710
0.1195 Systemic lupus
erythematosus
:path:hsa05322
0.1862
Focal adhesion
:path:hsa04510
0.1252 Pathways
in cancer
:path:hsa05200
0.1969
Notch signal-
ing pathway
:path:hsa04330
0.1486 Cell cycle
:path:hsa04110
0.2104
Pathways
in cancer
:path:hsa05200
0.1567 Small cell
lung cancer
:path:hsa05222
0.2221
Table 4.3: Comparison between WSPIAGG and SPIA in Basal-like subtype
has implications becasue the BRCA1 gene is responsible for DNA damage repair.
Therefore, it is quite plausible to infer that this subtype of cancer will have much
more significant chromosomal aberrations associated with it leading to much more
consistency being picked up by the WSPIAGG method.
Pathways Of Interest
WSPIAGG identified several pathways that showed consistent activity across tu-
mors samples that have been linked to cancer.
Pathways of particular interest were DNA Damage Response, mTOR signal-
40
Figure 4.1: Pathway activity as measured by WSPIAGG in Basal-like subtype
Figure 4.2: Pathway activity as measured by SPIA in Basal-like subtype
ing, and Notch Signaling, all of which have been implicated in cancer and specif-
ically breast cancer in the case of DNA Damage Response [34, 35, 36]. Further
investigation into the GISTIC genes in these pathways may be worthwhile.
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Notable Pathways
Pathway Name Database(s)
G1 To Cell Cycle Control Wikipathways
Focal Adhesion KEGG and Wikipathways
Cell Cycle KEGG and WikiPathways
mTor signaling Pathway KEGG
Notch Signaling KEGG
ErbB signaling Pathway KEGG
DNA Damage Response (only ATM dependent) Wikipathways
Complement and Coagulation Cascades KEGG
Antigen Processing and presentation KEGG
Apoptosis Wikipathways
Table 4.4: Active pathways in Basal-like subtype
ClusterGroup Observed Expected P-value
0 20 17.74 0.335
1 2 2.79 0.615
2 2 2.12 0.930
3 7 8.21 0.592
4 9 4.61 0.0231
Table 4.5: Logrank test for each clustered group in Basal-like subtype
Overall Survival Analysis
In order to determine whether any of the samples in the Basal-like subtypes that
displayed similar pathway deregulation had similar over survival rates, tumor sam-
ples were grouped into five main clusters using hierarchical clustering with complete
linkage. The logrank test was used to identify the significance between each of the
different groups across the entire timeline measured.
Group 4 demonstrated a significant difference between the other groups
combined. Using Kaplan Meir’s survival probability estimate, group 4 was plotted
versus the other groups combined.
The results demonstrated group 4 having a lower overall survival than it’s
counterparts.
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Figure 4.3: Overall survival plots for clustered group 4 in Basal-like subtype
Luminal Complex
Comparison Results
In looking at the average p-values across the samples, WSPIAGG scored worse in
most cases than SPIA.
However, it is worth noting two observations. First, WSPIAGG ranked path-
ways more closely related to cancer higher then SPIA such as Cytokine-cytokine
receptor interaction, and Focal adhesion. Second, the pathway activity measured
across samples indicates that WSPIAGG found much more pathway deregulation
consistently at lower p-values across tumor samples then SPIA.
Pahtways Of Interest
Similar to Basal-like, Luminal complex had notable activity in the Notch Signal-
ing, DNA Damage Response and Focal adhesion which as previously stated have
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WSPIAGG SPIA
Pathway Name Ave P-value Pahtway Name Ave P-value
Melanoma
:path:hsa05218
0.0731 Complement
and Coagu-
lation Cas-
cades:WP558
0.0927
Pathways
in cancer
:path:hsa05200
0.0973 Complement
and coagula-
tion cascades
:path:hsa04610
0.1024
Cytokine-
cytokine re-
ceptor interaction
:path:hsa04060
0.1994 ECM-receptor
interaction
:path:hsa04512
0.1692
Focal adhesion
:path:hsa04510
0.3102 Systemic lupus
erythematosus
:path:hsa05322
0.1723
Insulin signal-
ing pathway
:path:hsa04910
0.3606 Focal adhesion
:path:hsa04510
0.1931
Cell cycle
:path:hsa04110
0.3705 Cytokine-
cytokine re-
ceptor interaction
:path:hsa04060
0.2067
Complement
and coagula-
tion cascades
:path:hsa04610
0.3989 Endochondral
Ossifica-
tion:WP474
0.2169
ECM-receptor
interaction
:path:hsa04512
0.4277 Focal Adhe-
sion:WP306
0.2176
Table 4.6: Comparison between WSPIAGG and SPIA in Luminal Complex subtype
demonstrated a significant role in cancer [36, 35, 37]. This may indicate that the
more aggressive subtypes of cancer deregulate similar signaling pathways. It may
be worthwhile to map the GISTIC genes that are shared between Luminal Com-
plex and Basal-like for further analysis. A list of the more notable active pathways
associated with cancer for Luminal Complex is provided.
Again, DNA Damage Response was identified as a pathway with consistent
activity across tumor samples. Luminal complex subtype has been associated with
BRCA2 mutated tumors [5]. Similar to the BRCA1 gene, the BRCA2 gene is re-
sponsible for DNA damage repair making it feasible to see significant amount of
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Figure 4.4: Pathway activity as measured by WSPIAGG in Luminal Complex sub-
type
Figure 4.5: Pathway activity as measured by SPIA in Luminal Complex subtype
chromosomal aberrations in these types of tumors with the malfunctioning of the
DNA Damage Response pathway.
Overall Survival Analysis
Hierarchical clustering with complete linkage was applied to these samples as well
which resulted in five different groups being identified. There was a significant
difference between group 4 and the other groups combined with respect to overall
survival.
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Notable Pathways
Pathway Name Database(s)
G1 To Cell Cycle Control Wikipathways
Focal Adhesion KEGG and Wikipathways
Notch Signaling KEGG
DNA Damage Response (only ATM dependent) Wikipathways
ECM-receptor interaction KEGG
Table 4.7: Active pathways in Luminal Complex subtype
ClusterGroup Observed Expected P-value
0 34 33.1 0.743
1 8 4.4 0.0573
2 7 3.95 0.111
3 20 24.5 0.237
4 6 13.8 0.0107
Table 4.8: Logrank test for each clustered group in Luminal Complex subtype
However, in this case group 4 appeared to have a higher survival curve then
it’s counterparts.
Group 1 also demonstrated a slight differentiation compared to the other
groups combined displaying a worse overall survival curve but not within an appli-
cable significance range.
17q12
Comparison Results
As within the previous subtypes, SPIA scored better on average across tumor sam-
ples then WSPIAGG. However, WSPIAGG as in the other subtypes as well identified
much more pathway activity then SPIA.
There wasn’t as noticeable the amount of pathway activity as was the case
in Basal-like and Luminal complex. However, different pathways still displayed con-
sistent activity across tumor samples.
46
Figure 4.6: Overall survival plots for clustered group 4 in Luminal Complex subtype
Pathways Of Interest
The most notable pathway to be identified using WSPIAGG as active in a significant
number of samples was ErbB2 signaling pathway. This is significant because 17q12
shares similar molecular and clinical characteristics to ErbB2+/Her2− subtype of
cancer [25].
Insulin signaling pathways have also been implicated in cancer development
[38]. Other pathways such as apoptosis have been well established of requiring
deregulation in order for tumorigenesis to occur.
Overall Survival Analysis
There were no subgroups in 17q12 subtype that displayed significantly better or
worse overall survival differences.
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WSPIAGG SPIA
Pathway Name Ave P-value Pahtway Name Ave P-value
Small cell
lung cancer
:path:hsa05222
0.1023 Complement
and Coagu-
lation Cas-
cades:WP558
0.0599
Neuroactive
ligand-receptor
interaction
:path:hsa04080
0.2074 Complement
and coagula-
tion cascades
:path:hsa04610
0.0977
Pathways
in cancer
:path:hsa05200
0.2595 Cytokine-
cytokine re-
ceptor interaction
:path:hsa04060
0.1560
Insulin signal-
ing pathway
:path:hsa04910
0.2679 ECM-receptor
interaction
:path:hsa04512
0.1611
Cell cycle
:path:hsa04110
0.3417 Focal adhesion
:path:hsa04510
0.1847
Focal adhesion
:path:hsa04510
0.3653 Focal Adhe-
sion:WP306
0.1943
Cytokine-
cytokine re-
ceptor interaction
:path:hsa04060
0.4323 Melanoma
:path:hsa05218
0.2789
Prostate cancer
:path:hsa05215
0.4494 TGF Beta Sig-
naling Path-
way:WP560
0.2979
TGF-beta sig-
naling pathway
:path:hsa04350
0.5653 Regulation
of actin cy-
toskeleton
:path:hsa04810
0.3056
Table 4.9: Comparison between WSPIAGG and SPIA in 17q12 subtype
Notable Pathways
Pathway Name Database(s)
Focal Adhesion KEGG and Wikipathways
ECM-receptor interaction KEGG
Insulin signaling pathways KEGG
ErbB signaling Pathway KEGG and Wikipathways
Signaling Of Heptocyte Growth Factor Receptor Wikipathways
Apoptosis Wikipathways and KEGG
Alpha 6-Beta 4 Integrin signaling pathway Wikipathways
Table 4.10: Active pathways in 17q12 subtype
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Figure 4.7: Pathway activity as measured by WSPIAGG in 17q12 subtype
Figure 4.8: Pathway activity as measured by SPIA in 17q12 subtype
Luminal Simple
Comparison Results
Adhering to the same trends, SPIA scored on average better than WSPIAGG across
the different samples.
Again, WSPIAGG detected much more consistent activity across samples
versus SPIA. Compared to the other subtypes, this subtype did not demonstrate
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ClusterGroup Observed Expected P-value
1 4 4.27 0.881
2 6 4.71 0.491
3 3 2.41 0.675
4 5 7.07 0.324
Table 4.11: Logrank test for each clustered group in 17q12 subtype
WSPIAGG SPIA
Pathway Name Ave P-value Pahtway Name Ave P-value
Cytokine-
cytokine re-
ceptor interaction
:path:hsa04060
0.0824 Cytokine-
cytokine re-
ceptor interaction
:path:hsa04060
0.1846
ECM-receptor
interaction
:path:hsa04512
0.1209 Systemic lupus
erythematosus
:path:hsa05322
0.1861
Focal adhesion
:path:hsa04510
0.2911 ECM-receptor
interaction
:path:hsa04512
0.2042
Neuroactive
ligand-receptor
interaction
:path:hsa04080
0.3044 Focal adhesion
:path:hsa04510
0.2138
T cell recep-
tor signal-
ing pathway
:path:hsa04660
0.5268 Focal Adhe-
sion:WP306
0.2676
Insulin signal-
ing pathway
:path:hsa04910
0.5386 TGF Beta Sig-
naling Path-
way:WP560
0.2890
Regulation
of actin cy-
toskeleton
:path:hsa04810
0.5807 Pathways
in cancer
:path:hsa05200
0.2968
Cell cycle
:path:hsa04110
0.6501 Cell cycle
:path:hsa04110
0.3302
Axon guidance
:path:hsa04360
0.6951 Cell cy-
cle:WP179
0.3592
Table 4.12: Comparison between WSPIAGG and SPIA in Luminal Simple subtype
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Figure 4.9: Overall survival plots for clustered groups in 17q12 subtype
Notable Pathways
Pathway Name Database(s)
Focal Adhesion KEGG and Wikipathways
ECM-receptor interaction KEGG
Cytokine-Cytokine Receptor Interaction Wikipathways
Neuroactie ligand-receptor Interaction KEGG
Table 4.13: Active pathways in Luminal Simple subtype
large amounts of pathway activity using WSPIAGG method. This may correspond
to research evidence suggesting a less aggressive form of breast cancer compared
to the other subtypes [26, 25].
Pathways Of Interests
Corresponding to pathway activity, not many pathways were identified as notable.
Cytokine-Cytokine Receptor Interaction has been implicated in cancer [39]
and apoptosis is a well known pathways that must be deregulated for tumorigenesis
to occur.
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Figure 4.10: Pathway activity as measured by WSPIAGG in Luminal Simple subtype
Figure 4.11: Pathway activity as measured by SPIA in Luminal Simple subtype
Overall Survival Analysis
Luminal Simple did not have any subgroups that faired better or worse with respect
to overall analysis.
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Figure 4.12: Overall survival plots for clustered groups in Luminal Simple subtype
ClusterGroup Observed Expected P-value
0 4 5.68 0.188
1 1 1.41 0.702
2 3 3.66 0.638
3 0 0.614 0.324
Table 4.14: Logrank test for each clustered group in Luminal Simple subtype
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Chapter 5
DISCUSSION
The pathways identified as notable in the different subtypes are a who’s-who of
pathways implicated in cancer. Since there’s an argument to be made that every
signaling pathway may be implicated, WSPIAGG not only identifies these pathways
but points to a solid source, in the GISTIC genes, of what could be causing deregu-
lation. As a point of interest, the same two pathways were consistently identified in
the different subtypes of breast cancer. Focal Adhesion and ECM-receptor interac-
tion were found in all four of the subtypes. Further research of these pathways may
be useful in breast cancer.
The use of WSPIAGG was of mixed results compared to SPIA. On one hand,
SPIA had lower p-values for pathway activity then WSPIAGG on average across
the majority of subtypes. On the other hand, WSPIAGG was capable of identifying
more pathways as being deregulated more consistently across tumor samples in
each of the four subtypes of breast cancer analyzed. This may be explained by
the fact that WSPIAGG is reliant upon GISTIC gene activity to determine pathway
activity. If GISTIC gene activity is low or if the number of GISTIC genes found in
a pathway is not significant then it can severely effect the overall score given to a
pathway. Thus, although more pathways were found across the samples to have a
lower p-value for SPIA, there could have been a certain number of pathways that
did not have significant GISTIC activity or presence that skewed the p-value for
WSPIAGG. Given that significant mutations and differential expression are high in
the Basal-like subtype, consistent with clinical research, this may explain why the
Basal-like subtype was the only subtype to have pathways p-value scores lower on
average using WSPIAGG.
Nevertheless, WSPIAGG was capable of demonstrating significant results
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in identifying pathways associated with cancer for each of the different subtypes
analyzed. In particular, identifying ErbB2 signaling pathways in the 17q12 analysis.
It also demonstrated the ability to identify the same pathways as SPIA but with much
more consistency of lower p-values across tumor samples. Ultimately, the overall
objective was to introduce copy number data into signaling pathway analysis and
obtain just as good, if not better, results. Given the results previously introduced,
copy number data should be taken into consideration when determining pathway
deregulation.
Future Research
The current research focused on using KEGG and Wikipathways databases limiting
the scope to the information they provided. As Pathway Commons migrates to
BioPAX level 3, it will be possible to incorporate a much greater number of signaling
pathways to analyze. In addition, as more databases move to a centralized method
of storing and representing signaling pathway data, the ease of implementing new
databases in proprietary software developed will allow for better and more efficient
analysis of signaling pathways.
In addition, proteomics continues to expand the amount of new information
with respect to signal transduction and signaling pathways. The inclusion of the data
provided by the proteomics field will be of vital importance, especially in signaling
pathway analysis. Signaling pathways rely upon a number of different proteins from
ligands to enzymes, to ensures proper intercellular and intracellular communication.
Incorporating this data into signaling pathway analysis will undoubtedly assist in
describing pathway regulation and deregulation.
Finally, as copy number data availability continues to increase for cancer
datasets, it will be possible to apply this method to other types of cancer as well.
This may prove useful in better understanding the role that gene aberrations play
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in deregulated pathways across different types of cancer with a sincere hope that it
leads to better, more efficient cancer therapies.
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